Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Leire Pérez-Latorre has a total of 88 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prevalence and cardiovascular associations of elevated lipoprotein(a) in people living with HIV: A cross-sectional study

    by Marta Lago, Marta Salas, Ana Torres, Cristina Diez, Chiara Fanciulli, Leire Perez, Francisco Tejerina, Elena Bello, Jose Maria Bellon, Patricia Muñoz, et al.


  • Open Access

    Sex and age-related differences in humoral and cellular responses to the recombinant zoster vaccine in people living with HIV

    by Cristina Díez, Carlos Pita-Martínez, Marta Quero-Delgado, Aurora Gómez-Tórtola, Chiara Fanciulli, Ana Marchan, Teresa Aldámiz-Echevarría, Daniel Sepúlveda-Crespo, Francisco Tejerina, Leire Pérez-Latorre, et al.

  • Open Access

    Chronic Systemic SARS-CoV-2 Infection Without Respiratory Involvement in an Immunocompromised Patient

    by Francisco Tejerina, Daniel Peñas-Utrilla, Marta Herranz, Pilar Catalán, Mercedes Marín, Lara Mesones, José Manuel García-Domínguez, Beatriz Merino, Leire Pérez, Chiara Fanciulli, et al.

    In a patient on immunosuppressant treatment, SARS-CoV-2 RNA was documented in different extra-respiratory samples over several months in the absence of positive determinations in upper respiratory samples. Whole-genome sequencing of these samples showed the acquisition of different single-nucleotide polymorphisms over time, suggesting viral evolution and thus viral viability.


  • Open Access

    Altered blood microbiome in patients with HCV-related Child-Pugh class B cirrhosis

    by Oscar Brochado-Kith, Marta Rava, Juan Berenguer, Juan González-García, David Rojo, Cristina Díez, Victor Hontañon, Ana Virseda-Berdices, Luis Ibañez-Samaniego, Elba Llop-Herrera, et al.


  • Open Access

    Patterns of Sexualized Drug Use among Gay, Bisexual, and Other Men Who Have Sex with Men Living with HIV: Insights from a Comprehensive Study—The U-SEX-2 GESIDA 9416 Study

    by Pablo Ryan, Helen Dolengevich-Segal, Luis Ramos-Ruperto, Alfonso Cabello, Matilde Sanchez-Conde, Jorge Vergas, Jorge Valencia, Guillermo Cuevas, José Sanz, Javier Curto-Ramos, et al.

    Background: Sexualized drug use (SDU) has become a public health concern in recent years. This study aimed to estimate the prevalence of SDU in gay, bisexual, and other men who have sex with men living with HIV (HIV + GBMSM) in Madrid during 2019/2020 and compare it with data from 2016/2017 in order to detect changes in patterns. Methods: We analyzed the frequency of SDU in a sample of HIV + GBMSM attending HIV clinics, who participated in an anonymous online survey regarding sexual behavior and recreational drug use. The association between SDU, sexual risk behaviors, and STIs was evaluated. Results: This study included 424 HIV + GBMSM, with a mean age of 40 (10.43) years. Overall, 94% (396) reported being sexually active. Additionally, 33% (140) had been diagnosed with an STI within the previous year. Moreover, 54% (229) had used drugs in the last year, 25% (107) engaged in SDU, and 16% (17) reported engagement in slamsex. After adjusting for confounding factors, SDU was associated with STIs, fisting, unprotected anal intercourse, and having >24 sexual partners in the last year. According to the DUDIT test scores, 80% (81) probably had problematic drug use (≥6 points), and 8% (8) probable drug dependence (≥25 points). When comparing the U-SEX-1 (2016/2017) data with the U-SEX-2 (2019/2020) data, no significant differences were found in the proportion of participants practicing SDU or slamming. Conclusions: The prevalence of SDU among HIV + GBMSM has remained high in recent years and without significant changes. The risk of problematic drug use among those who practice SDU is high. We observed a clear association between SDU, high-risk sexual behaviors, and STIs.


  • Open Access

    Trends and Patterns of Sexualised Drug Use among HIV-Positive Gay, Bisexual and Other Men Who Have Sex with Men: Insights from a Comprehensive Study in a Major European City - The U-SEX-2 GESIDA 9416 Study

    by Pablo Ryan, Helen Dolengevich-Segal, Luis Ramos-Ruperto, Alfonso Cabello, Matilde Sanchez-Conde, Jorge Vergas, Jorge Valencia, Guillermo Cuevas, Jose Sanz-Moreno, Javier Curto-Ramos, et al.

    Background: This study aimed to estimate the prevalence of sexualized drug use (SDU) in gay, bisexual, and other men who have sex with men living with HIV (HIV+GBMSM) in Madrid during 2019/2020 and compare it with data from 2016/2017. Methods: We analysed the frequency of SDU in a sample of HIV+GBMSM attending HIV clinics, who participated in an anonymous online survey regarding sexual behaviour and recreational drug use. The association between SDU, sexual risk behaviours, and STIs was evaluated. The methodology employed in the present study(U-SEX-2) in 2019/2020 was consistent with that of a previous study(U-SEX-1) in 2016/2017. Results: The study included 424 HIV+GBMSM, with a mean age of 40(10.43) years. Overall, 94% (396) reported being sexually active. Additionally, 33% (140) had been diagnosed with an STI within the previous year. Moreover, 54% (229) had used drugs in the last year, 25% (107) engaged in SDU, and 15% (17) reported engagement in slamsex. After adjusting for confounding factors, SDU was associated with STIs, fisting, unprotected anal intercourse, and having > 24 sexual partners in the last year. According to the DUDIT test scores, 76% (81) probably had problematic drug use (≥6 points), and 5% (8) probable drug dependence (≥25 points). When comparing the U-SEX-1(2016/2017) data with the U-SEX-2(2019/2020) data, no significant differences were found in the proportion of participants practicing SDU or slamsex. Conclusion: The prevalence of SDU among HIV+GBMSM has remained high in recent years and without significant changes. We observed a clear association between SDU, high-risk sexual behaviors, STIs, and the risk of drug related problems.


  • Open Access

    PBMCs gene expression signature of advanced cirrhosis with high risk for clinically significant portal hypertension in HIV/HCV coinfected patients: A cross-control study

    by Sergio Salgüero, Óscar Brochado-Kith, Ana Virseda Verdices, Juan Berenguer, Juan González-García, Isidoro Martínez, Cristina Díez, Víctor Hontañón, Leire Pérez-Latorre, Amanda Fernández-Rodríguez, et al.


  • Open Access

    Metabolomic changes after DAAs therapy are related to the improvement of cirrhosis and inflammation in HIV/HCV-coinfected patients

    by Ana Virseda-Berdices, David Rojo, Isidoro Martínez, Juan Berenguer, Juan González-García, Oscar Brochado-Kith, Amanda Fernández-Rodríguez, Cristina Díez, Víctor Hontañon, Leire Pérez-Latorre, et al.


  • Open Access

    Different Within-Host Viral Evolution Dynamics in Severely Immunosuppressed Cases with Persistent SARS-CoV-2

    by Laura Pérez-Lago, Teresa Aldámiz-Echevarría, Rita García-Martínez, Leire Pérez-Latorre, Marta Herranz, Pedro J. Sola-Campoy, Julia Suárez-González, Carolina Martínez-Laperche, Iñaki Comas, Fernando González-Candelas, et al.

    A successful Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variant, B.1.1.7, has recently been reported in the UK, causing global alarm. Most likely, the new variant emerged in a persistently infected patient, justifying a special focus on these cases. Our aim in this study was to explore certain clinical profiles involving severe immunosuppression that may help explain the prolonged persistence of viable viruses. We present three severely immunosuppressed cases (A, B, and C) with a history of lymphoma and prolonged SARS-CoV-2 shedding (2, 4, and 6 months), two of whom finally died. Whole-genome sequencing of 9 and 10 specimens from Cases A and B revealed extensive within-patient acquisition of diversity, 12 and 28 new single nucleotide polymorphisms, respectively, which suggests ongoing SARS-CoV-2 replication. This diversity was not observed for Case C after analysing 5 sequential nasopharyngeal specimens and one plasma specimen, and was only observed in one bronchoaspirate specimen, although viral viability was still considered based on constant low Ct values throughout the disease and recovery of the virus in cell cultures. The acquired viral diversity in Cases A and B followed different dynamics. For Case A, new single nucleotide polymorphisms were quickly fixed (13–15 days) after emerging as minority variants, while for Case B, higher diversity was observed at a slower emergence: fixation pace (1–2 months). Slower SARS-CoV-2 evolutionary pace was observed for Case A following the administration of hyperimmune plasma. This work adds knowledge on SARS-CoV-2 prolonged shedding in severely immunocompromised patients and demonstrates viral viability, noteworthy acquired intra-patient diversity, and different SARS-CoV-2 evolutionary dynamics in persistent cases.


  • Open Access

    European mitochondrial haplogroups predict liver-related outcomes in patients coinfected with HIV and HCV: a retrospective study

    by Teresa Aldámiz-Echevarría, Salvador Resino, José M. Bellón, María A. Jiménez-Sousa, Pilar Miralles, Luz M. Medrano, Ana Carrero, Cristina Díez, Leire Pérez-Latorre, Chiara Fanciulli, et al.

    Mitochondrial DNA (mtDNA) haplogroups have been associated with advanced liver fibrosis and cirrhosis in patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV). Our aim was to determine whether mtDNA haplogroups are associated with liver-related events (LREs) in HIV/HCV-coinfected patients. We carried out a retrospective cohort study in HIV/HCV-coinfected patients who were potential candidates for therapy with interferon and ribavirin (IFN/Rib) between 2000 and 2009. The primary endpoint was the occurrence of LREs (decompensation or hepatocellular carcinoma). mtDNA genotyping was performed using the Sequenom MassARRAY platform. We used Fine and Gray proportional hazards model to test the association between mtDNA haplogroups and LREs, considering death as a competitive risk. The study population comprised 243 patients, of whom 40 had advanced fibrosis or cirrhosis. After a median follow-up of 7.7 years, 90 patients treated with IFN/Rib achieved sustained viral response (SVR), 18 patients had LREs, and 11 patients died. Patients with haplogroup H had lower cumulative incidence than patients with other haplogroups (p = 0.012). However, patients with haplogroup T had higher cumulative incidence than patients with other haplogroups (p = 0.074). In the multivariate analysis, haplogroup T was associated with an increased hazard of developing LREs [adjusted subhazard ratio (aSHR) = 3.56 (95% CI 1.13;11.30); p = 0.030]; whereas haplogroup H was not associated with lower hazard of LREs [aSHR = 0.36 (95% CI 0.10;1.25); p = 0.105]. When we excluded patients who achieved SVR during follow-up, we obtained similar SHR values. European mitochondrial haplogroups may influence the natural history of chronic hepatitis C.